SpyGlass Pharma, Inc.
SGP- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0001778922
No open-market purchases or sales by SpyGlass Pharma, Inc. insiders were filed in the last 90 days; 52 institutions reported holding it in 13F filings for Q2 2026, worth $581.1M in total; no superinvestor holds it.
Q2 2026 vs. Q1 2026
How the institutions holding SpyGlass Pharma, Inc. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Q2 2026 | Change |
|---|---|---|---|
| Holders | 35 | 52 | +17 |
| Shares | 25.4M | 26.1M | +769.5K (+3.0%) |
| Value | $655.4M | $581.1M | −$74.3M (−11.3%) |
New holders (22)
Institutions that held SpyGlass Pharma, Inc. at the end of Q2 2026 but not at the end of Q1 2026.
Sold out (5)
Institutions that held SpyGlass Pharma, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| First Light Asset Management, LLC | 375,000 | $9.72M |
| Monashee Investment Management LLC | 95,000 | $2.46M |
| Marshall Wace, LLP | 29,348 | $760.4K |
| Goldman Sachs Group Inc | 19,283 | $499.6K |
| Squarepoint Ops LLC | 7,811 | $202.4K |